Clinical Trial Search

Primary: Probability of Remission [16-item Quick Inventory of Depressive Symptomatology (QIDS-SR) Score Less Than or Equal to 5 at 12-Week Endpoint] — 0.36; 0.32 Probability of…

Primary: Normalized Net Incremental Area Under the Curve (AUC) for the Bath Ankylosing Spondylitis Disease Activities Index (BASDAI) Between Randomization and Week 12 — -19.79…

Primary: Sustained Virological Response (SVR) — 19; 22 Percentage of participants — p=0.6119

Primary: Preferred Contrast Agent — 25; 29; 117; 116 participants — p=<0.001

Primary: Number of Subjects With Clinically Significant Upper and/or Lower Gastrointestinal Events (CSULGIEs) — 20; 81 participants — p=<0.0001

Primary: Percentage Change in Low Density Lipoprotein-Cholesterol (LDL-C) From Baseline at Study Endpoint, After 8 Weeks of Treatment — -26.56; -9.7 Percentage change — p=.0026

Primary: Area Under the Concentration Versus Time Curve for 0 to 24 Hours After Drug Administration, Done Between Days 9 and 12 of the Menstrual Cycle at Time 1 (Before) and Time…

Primary: Change (Reduction) in Triglycerides Levels From Baseline to End of Treatment (Week 8) — 67.95; 78.61; 22.31 mg/dL

Primary: Proportion of Subjects Achieving Haemostasis at 3 Minutes — 0.746; 0.333 Proportion of Subjects — p=<0.0001

Primary: Secretory Conversion of the Endometrium — 23; 28; 70; 53 participants

Primary: Mean Change From Baseline in the International Restless Legs Syndrome (IRLS) Rating Scale Total Score at Week 12 and Week 26 — -12.1; -14.2; -13.4; -15.9 points on a…

Primary: Number and Severity of Infusion Site Reactions (ISRs) Using a Modified ISR Reporting Scale for Phlebitis and Infiltration in Patients Treated With Dose Regimen 1 and…

Primary: Number of Days of Unscheduled Blood Loss - Cycle 1 — 1.9; 2.0 Days — p=0.9698

Primary: Incidence of Nausea and Vomiting — 25; 32 participants — p=<0.05

Primary: Number of Subjects With a 4 Week Continuous Quit Rate (CQR) From Smokeless Tobacco — 125; 85 participants — p=<0.0001